US FDA's Temple On Real-World Evidence: 'I Find The Whole Thing Very Frustrating'
Executive Summary
CDER deputy director for clinical science reiterates his long-held skepticism about whether real-world evidence can be used to demonstrate efficacy claims.
You may also be interested in...
Real-World Evidence, Digital Health, Insurance Coverage Reforms On Cures 2.0 Agenda
All three areas need work following enactment of the original 21st Century Cures Act, authors Fred Upton and Diana DeGette write in vision statement.
Keeping Track: Industry Beefs Up 2020 Review Pipeline With Submissions Galore
The latest drug development news and highlights from our US FDA Performance Tracker.
Real-World Evidence: Sponsors Look To US FDA Drug Reviews For Potential Pitfalls
Methodological problems with RWE submissions for approved applications may give sponsors ‘a little bit of a pause’ as they work through data selection and analytical issues, Aetion’s Jeremy Rassen says. CDER’s Janet Woodcock says it is easier to use RWE when treatment effects are large.